Histopathological Evaluation and Analysis of Immunohistochemical Markers p53 and CD44S in Renal Cell Carcinoma: A Cross-sectional Study

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH Pub Date : 2023-01-01 DOI:10.7860/jcdr/2023/63352.18192
Shivani Gupta, C. W. Devadass, Shubham Varshney, Sml Prakash Babu
{"title":"Histopathological Evaluation and Analysis of Immunohistochemical Markers p53 and CD44S in Renal Cell Carcinoma: A Cross-sectional Study","authors":"Shivani Gupta, C. W. Devadass, Shubham Varshney, Sml Prakash Babu","doi":"10.7860/jcdr/2023/63352.18192","DOIUrl":null,"url":null,"abstract":"Introduction: Renal Cell Carcinoma (RCC) is the 9th and 14th most common cancer in men and women, respectively, and among the most lethal urological cancers. Upto 30% of patients experience recurrence within five years postnephrectomy. Therefore, the predictors of disease survival and molecular markers associated with clinical prognostic parameters should be identified. Aim: To examine the histopathological features of RCC and investigate the association of Tumour protein p53 (p53) and Cluster of Differentiation 44S (CD44S) expression with prognostic factors. Materials and Methods: The present prospective crosssectional study was conducted in the Department of Pathology, M.S Ramaiah Medical College and Hospitals, Bengaluru, Karnataka, India, from June 2017 to May 2019. Radical and partial nephrectomy specimens of RCC patients were obtained for the study. In each case age, tumour histologic type, tumour size, Fuhrman nuclear grade, rhabdoid features, necrosis, tumour stage and p53 and CD44S status were evaluated through immunohistochemistry. The Chi-square test was used to evaluate differences in CD44S and p53 expression among different groups. Data were entered in Microsoft (MS) Excel version 11 and was analysed using International Business Machines Statistical Package for the Social Sciences (IBM SPSS) software version 20.0. Results: The study included 50 RCC patients with a mean age of 56.64 years and male:female ratio was 2.8:1. CD44S and p53 positivity were noted in 33 (66%) and 27 (54%) patients, respectively. Weak, moderate, and strong CD44S expression were observed in 13 (26%), 8 (16%) and 12 (24%) patients, respectively and those of p53 in 9 (18%), 14 (28%) and 13 (26%) patients, respectively. Patients with higher Fuhrman nuclear grades exhibited stronger CD44S (n=24, 85.71%) and p53 (n=19, 67.85%) expression than did those with lower grades. Conclusion: The clear cell carcinoma is the most common histologic subtype. Presence of rhabdoid features and necrosis is seen with advanced Tumour, Nodal and Metastasis (TNM) stage. A significant association between p53 and CD44S immunohistochemical expression and higher Fuhrman nuclear grade suggests increased expression of p53 and CD44S and indicates an aggressive clinical course that can be used as a marker of poor prognosis.","PeriodicalId":15483,"journal":{"name":"JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH","volume":"27 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7860/jcdr/2023/63352.18192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Renal Cell Carcinoma (RCC) is the 9th and 14th most common cancer in men and women, respectively, and among the most lethal urological cancers. Upto 30% of patients experience recurrence within five years postnephrectomy. Therefore, the predictors of disease survival and molecular markers associated with clinical prognostic parameters should be identified. Aim: To examine the histopathological features of RCC and investigate the association of Tumour protein p53 (p53) and Cluster of Differentiation 44S (CD44S) expression with prognostic factors. Materials and Methods: The present prospective crosssectional study was conducted in the Department of Pathology, M.S Ramaiah Medical College and Hospitals, Bengaluru, Karnataka, India, from June 2017 to May 2019. Radical and partial nephrectomy specimens of RCC patients were obtained for the study. In each case age, tumour histologic type, tumour size, Fuhrman nuclear grade, rhabdoid features, necrosis, tumour stage and p53 and CD44S status were evaluated through immunohistochemistry. The Chi-square test was used to evaluate differences in CD44S and p53 expression among different groups. Data were entered in Microsoft (MS) Excel version 11 and was analysed using International Business Machines Statistical Package for the Social Sciences (IBM SPSS) software version 20.0. Results: The study included 50 RCC patients with a mean age of 56.64 years and male:female ratio was 2.8:1. CD44S and p53 positivity were noted in 33 (66%) and 27 (54%) patients, respectively. Weak, moderate, and strong CD44S expression were observed in 13 (26%), 8 (16%) and 12 (24%) patients, respectively and those of p53 in 9 (18%), 14 (28%) and 13 (26%) patients, respectively. Patients with higher Fuhrman nuclear grades exhibited stronger CD44S (n=24, 85.71%) and p53 (n=19, 67.85%) expression than did those with lower grades. Conclusion: The clear cell carcinoma is the most common histologic subtype. Presence of rhabdoid features and necrosis is seen with advanced Tumour, Nodal and Metastasis (TNM) stage. A significant association between p53 and CD44S immunohistochemical expression and higher Fuhrman nuclear grade suggests increased expression of p53 and CD44S and indicates an aggressive clinical course that can be used as a marker of poor prognosis.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肾细胞癌中免疫组织化学标志物p53和CD44S的组织病理学评价和分析:一项横断面研究
导读:肾细胞癌(RCC)在男性和女性中分别是第9位和第14位最常见的癌症,也是最致命的泌尿系统癌症之一。高达30%的患者在肾切除术后5年内复发。因此,应该确定疾病生存的预测因子和与临床预后参数相关的分子标记。目的:探讨肿瘤蛋白p53 (p53)和分化簇44S (CD44S)表达与肾细胞癌预后的关系。材料与方法:本前瞻性横断面研究于2017年6月至2019年5月在印度卡纳塔克邦班加罗尔M.S Ramaiah医学院和医院病理科进行。本研究收集了肾细胞癌患者的全部和部分肾切除术标本。通过免疫组织化学方法对每例患者的年龄、肿瘤组织学类型、肿瘤大小、Fuhrman核分级、横纹肌特征、坏死、肿瘤分期及p53和CD44S状态进行评估。采用卡方检验评价CD44S、p53在不同组间的表达差异。数据在Microsoft (MS) Excel version 11中输入,并使用International Business Machines Statistical Package for the Social Sciences (IBM SPSS) version 20.0软件进行分析。结果:纳入RCC患者50例,平均年龄56.64岁,男女比例为2.8:1。CD44S阳性33例(66%),p53阳性27例(54%)。CD44S弱、中、强表达分别为13例(26%)、8例(16%)、12例(24%),p53表达分别为9例(18%)、14例(28%)、13例(26%)。Fuhrman核分级高的患者CD44S (n=24, 85.71%)和p53 (n=19, 67.85%)表达较低。结论:透明细胞癌是最常见的组织学亚型。在肿瘤、淋巴结和转移(TNM)晚期出现横纹肌样特征和坏死。p53和CD44S免疫组织化学表达与更高的Fuhrman核分级之间的显著关联表明p53和CD44S表达增加,表明临床病程具有侵袭性,可作为预后不良的标志。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH MEDICINE, GENERAL & INTERNAL-
自引率
0.00%
发文量
761
审稿时长
12 weeks
期刊介绍: Specialties Covered: Anaesthesia, Anatomy, Animal Research, Biochemistry, Biotechnology, Cardiology, Community, Dermatology, Dentistry, Education, Emergency Medicine, Endocrinology, Ethics, Ear Nose and Throat, Forensic, Gastroenterology, Genetics, Haematology, Health Management and Policy, Immunology and Infectious Diseases, Intensive Care, Internal Medicine, Microbiology, Health Management and Policy, Immunology and Infectious Diseases, Intensive Care, Internal Medicine, Microbiology, Nephrology / Renal, Neurology and Neuro-Surgery, Nutrition, Nursing/Midwifery, Oncology, Orthopaedics, Ophthalmology, Obstetrics and Gynaecology, Paediatrics and Neonatology Pharmacology, Physiology, Pathology, Plastic Surgery, Psychiatry/Mental Health, Rehabilitation / Physiotherapy, Radiology, Statistics, Surgery, Speech and Hearing (Audiology)
期刊最新文献
Correction. Correction. Correction. Correction. Mental Health of Foreign Medical Graduates in Tamil Nadu, India: A Mixed-methods Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1